Purple Biotech Ltd. [NASDAQ: PPBT] traded at a high on 02/18/21, posting a 10.20 gain after which it closed the day’ session at $6.16. The company report on January 18, 2021 that Purple Biotech to Present at the B. Riley Oncology Investor Conference.
Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, announced that the Purple Biotech management team will present a corporate overview at the B. Riley Oncology Investor Conference, being held virtually January 20-21, 2021.
Presentation Details Date: Wednesday, January 20Time: 10:30 AM ETWebcast: A live webcast of the presentation will be available on the investor section of the Purple Biotech website at www.purple-biotech.com. Following the live webcast, the event will remain archived on the Purple Biotech’s website for approximately 90 days.
The results of the trading session contributed to over 1620226 shares changing hands. Over the past one week, the price volatility of Purple Biotech Ltd. stands at 9.79% while the volatility over the past one month is 8.97%.
The market cap for PPBT stock reached $107.87 million, with 17.51 million shares outstanding and 15.45 million shares in the current float. Compared to the average trading volume of 838.41K shares, PPBT reached a trading volume of 1620226 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Purple Biotech Ltd. [PPBT]?
The Average True Range (ATR) for Purple Biotech Ltd. is set at 0.55, with the Price to Sales ratio for PPBT stock in the period of the last 12 months amounting to 107.87.
How has PPBT stock performed recently?
Purple Biotech Ltd. [PPBT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.22. With this latest performance, PPBT shares gained by 24.70% in over the last four-week period, additionally plugging by 17.20% over the last 6 months – not to mention a drop of -12.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PPBT stock in for the last two-week period is set at 63.62, with the RSI for the last a single of trading hit 64.00, and the three-weeks RSI is set at 62.90 for Purple Biotech Ltd. [PPBT]. The present Moving Average for the last 50 days of trading for this stock 4.49, while it was recorded at 5.87 for the last single week of trading, and 5.25 for the last 200 days.
Purple Biotech Ltd. [PPBT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Purple Biotech Ltd. [PPBT] shares currently have an operating margin of -739.60. Purple Biotech Ltd.’s Net Margin is presently recorded at -585.00.
Return on Total Capital for PPBT is now -66.38, given the latest momentum, and Return on Invested Capital for the company is -55.28. Return on Equity for this stock declined to -55.35, with Return on Assets sitting at -39.38. When it comes to the capital structure of this company, Purple Biotech Ltd. [PPBT] has a Total Debt to Total Equity ratio set at 2.14. Additionally, PPBT Total Debt to Total Capital is recorded at 2.10, with Total Debt to Total Assets ending up at 1.52. Long-Term Debt to Equity for the company is recorded at 0.27, with the Long-Term Debt to Total Capital now at 0.26.
Receivables Turnover for the company is 0.90 with a Total Asset Turnover recorded at a value of 0.07.
Insider trade positions for Purple Biotech Ltd. [PPBT]
There are presently around $7 million, or 14.49% of PPBT stock, in the hands of institutional investors. The top three institutional holders of PPBT stocks are: MORGAN STANLEY with ownership of 494,715, which is approximately 7958.56% of the company’s market cap and around 1.91% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 346,197 shares of the stock with an approximate value of $2.13 million in PPBT stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.79 million in PPBT stock with ownership of nearly New of the company’s market capitalization.
Positions in Purple Biotech Ltd. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 9 institutional holders increased their position in Purple Biotech Ltd. [NASDAQ:PPBT] by around 697,228 shares. Additionally, 5 investors decreased positions by around 14,210 shares, while 7 investors held positions by with 398,902 shares. The mentioned changes placed institutional holdings at 1,110,340 shares, according to the latest SEC report filing. PPBT stock had 4 new institutional investments in for a total of 166,197 shares, while 4 institutional investors sold positions of 13,710 shares during the same period.